

# Maeve Aine Lowery

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7829384/maeve-aine-lowery-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

143  
papers

6,128  
citations

31  
h-index

77  
g-index

156  
ext. papers

8,140  
ext. citations

4.5  
avg, IF

5.15  
L-index

#	Paper	IF	Citations
143	Patient knowledge, personal experience, and impact of the first wave of the COVID-19 pandemic in an Irish oncology cohort.. <i>Irish Journal of Medical Science</i> , <b>2022</b> , 1	1.9	
142	DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 749490	5.7	1
141	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 1194-1202	9.7	8
140	Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2021</b> , 15, 475-481	4.2	2
139	Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4004-4004	2.2	19
138	Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-cholangiocarcinoma. <i>Future Oncology</i> , <b>2021</b> , 17, 2057-2074	3.6	6
137	Modern oncological and operative outcomes in oesophageal cancer: the St. James's hospital experience. <i>Irish Journal of Medical Science</i> , <b>2021</b> , 190, 297-305	1.9	3
136	Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants. <i>Familial Cancer</i> , <b>2021</b> , 20, 97-101	3	1
135	Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	8
134	FLOT-regimen Chemotherapy and Transthoracic en bloc Resection for Esophageal and Junctional Adenocarcinoma. <i>Annals of Surgery</i> , <b>2021</b> , 274, 814-820	7.8	1
133	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , <b>2021</b> , 74, 1429-1444	11.2	14
132	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1669-1677	13.4	31
131	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , <b>2020</b> , 21, 796-807	21.7	264
130	The Cancer-Immune Set Point in Oesophageal Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 891	5.3	8
129	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. <i>Cancer</i> , <b>2020</b> , 126, 1995-2002	6.4	9
128	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline Mutation. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1378-1388	2.2	136
127	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 60-67	13.4	55

126	Liver and Bile Duct Cancer <b>2020</b> , 1314-1341.e11		3
125	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 433-444	4.3	52
124	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. <i>Investigational New Drugs</i> , <b>2020</b> , 38, 800-811	4.3	52
123	Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. <i>Cancer</i> , <b>2019</b> , 125, 4426-4434	6.4	28
122	Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 711-720	18.8	110
121	Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4096-4096	2.2	5
120	Prevalence of pancreaticobiliary cancer in Irish families with BRCA1 and BRCA2 mutations.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 210-210	2.2	
119	Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 937-945	12.9	15
118	Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2185-2193	12.9	22
117	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. <i>Cancer</i> , <b>2019</b> , 125, 1441-1448	6.4	8
116	Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 121-128	3.8	13
115	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1067-1074	9.7	103
114	Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e315-e321	3.8	6
113	Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. <i>Cancer</i> , <b>2018</b> , 124, 1374-1382	6.4	67
112	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1326-1336	12.9	198
111	Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2018</b> , 16, 50-58	7.3	22
110	Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e207-e216	3.8	6
109	A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4092-4092	2.2	4

108	Plasma KRAS as a biomarker for pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 316-316	2.2	2
107	Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 405-405	2.2	4
106	Prospective analysis of somatic and germline genetic alterations in patients with ampullary carcinomas.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 308-308	2.2	
105	Immunotherapy awareness in the oncology patient population: An Irish hospital experience.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15160-e15160	2.2	
104	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. <i>European Journal of Cancer</i> , <b>2018</b> , 89, 19-26	7.5	98
103	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 276-282	2.2	357
102	Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. <i>Cancers</i> , <b>2018</b> , 10,	6.6	8
101	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1540-1547	24.4	86
100	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4154-4161	12.9	182
99	Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes. <i>Journal of the American College of Surgeons</i> , <b>2017</b> , 224, 906-916	4.4	36
98	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , <b>2017</b> , 23, 703-713	50.5	1638
97	In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2Sdeoxy-2Sfluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models. <i>Molecular Imaging and Biology</i> , <b>2017</b> , 19, 885-892	3.8	14
96	Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. <i>PLoS ONE</i> , <b>2017</b> , 12, e0188022	3.7	43
95	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , <b>2017</b> , 2017,	3.6	699
94	Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy. <i>Journal of Gastrointestinal Oncology</i> , <b>2017</b> , 8, E65-E72	2.8	3
93	A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. <i>Cancer</i> , <b>2017</b> , 123, 4556-4565	6.4	40
92	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , <b>2017</b> , 318, 825-835	27.4	235
91	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6094-6100	12.9	107

90	A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model. <i>Translational Oncology</i> , <b>2017</b> , 10, 760-765	4.9	22
89	Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. <i>Acta Oncologica</i> , <b>2017</b> , 56, 1746-1753	3.2	23
88	Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4015-4015	2.2	65
87	Pharmacokinetic/pharmacodynamic (PK/PD) profile of AG-120 in patients with IDH1-mutant cholangiocarcinoma from a phase 1 study of advanced solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4082-4082	2.2	3
86	Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4102-4102	2.2	4
85	Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, in patients with pancreatic cancer and other CA19-9 positive malignancies.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4110-4110	2.2	4
84	Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15791-e15791	2.2	2
83	ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4142-TPS4142	2.2	14
82	Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 in patients (pts) with advanced, metastatic, or surgically unresectable cholangiocarcinoma (CCA) with inadequate response to prior therapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4145-TPS4145	2.2	4
81	A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 290-290	2.2	6
80	Analysis of prior malignancies in patients with cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 305-305	2.2	1
79	A phase I study of mFOLFOX6 and ADI-PEG-20 in patients (pts) with advanced hepatocellular carcinoma (HCC) and other gastrointestinal (GI) malignancies.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 384-384	2.2	1
78	Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 353-353	2.2	
77	Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 295-295	2.2	
76	Clinical impact of visceral thrombosis (VT) in pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 260-260	2.2	
75	Visceral thromboses (VT) in pancreas adenocarcinoma (PDAC): A systematic review.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 268-268	2.2	
74	Do pancreas cancer stem cells play crucial role in survival outcome?. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15721-e15721	2.2	
73	Mutational profiling of resected intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15675-e15675	2.2	1

72	Impact of care at Memorial Sloan Kettering Cancer Center (MSKCC): A comprehensive cancer center on overall survival (OS) in patients (pts) with AJCC stage IV pancreas adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e18128-e18128	2.2	
71	Brain metastases (BM) in pancreatic ductal adenocarcinoma (PDAC): Clinical and molecular characteristics.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15728-e15728	2.2	
70	A prospective analysis of germline alterations (GA) in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4085-4085	2.2	1
69	Early-onset pancreatic ductal adenocarcinoma (PDAC) at Memorial Sloan Kettering Cancer Center (MSKCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15736-e15736	2.2	
68	Current management and future directions in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , <b>2016</b> , 122, 3765-3775	6.4	14
67	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2016</b> , 10, 893-905	4.2	31
66	Abstract CT026: Phase I trial of HuMab-5B1 (MVT-5873), a novel monoclonal antibody targeting sLea, in patients with advanced pancreatic cancer and other CA19-9 positive malignancies <b>2016</b> ,		2
65	Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e15636-e15636	2.2	3
64	A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 335-335	2.2	37
63	Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 437-437	2.2	3
62	Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. <i>Chinese Clinical Oncology</i> , <b>2016</b> , 5, 62	2.3	101
61	Systemic therapy for biliary cancers. <i>Chinese Clinical Oncology</i> , <b>2016</b> , 5, 65	2.3	11
60	Presentation, clinical behavior, outcomes and therapies for patients with advanced pancreas adenocarcinoma (PAC) who present with or develop ascites.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 209-209	2.2	23
59	Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 244-244	2.2	
58	Genomic landscape of pancreatic adenocarcinoma: Does age matter?. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 250-250	2.2	
57	Assessment of genomic alterations in adenosquamous carcinoma of the pancreas (ASCOP).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 261-261	2.2	
56	Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e15635-e15635	2.2	
55	Do pancreatic cancer (PDA) stem cell markers predict biologic behavior?. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4112-4112	2.2	



54	Genomic profiling of pancreas ductal adenocarcinoma (PDA), actionability, and correlation with clinical phenotype.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4127-4127	2.2	1
53	Breast cancer resistance protein (ABCG2) as a potential biomarker for gemcitabine and nab-paclitaxel sensitivity.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4129-4129	2.2	
52	Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4088-4088	2.2	1
51	Phase 1B trial of ADI-PEG 20 (A) plus nab-Paclitaxel (nab-P) and gemcitabine (gem) in subjects with advanced pancreatic cancer (APC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e15756-e15756	2.2	
50	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. <i>Journal of Gastrointestinal Oncology</i> , <b>2016</b> , 7, 819-827	2.8	14
49	Young patients with synchronous colorectal liver metastases. <i>Journal of Surgical Oncology</i> , <b>2016</b> , 113, 473-6	2.8	4
48	Texture analysis for survival prediction of pancreatic ductal adenocarcinoma patients with neoadjuvant chemotherapy <b>2016</b> ,		2
47	Pancreas Adenocarcinoma: Ascites, Clinical Manifestations, and Management Implications. <i>Clinical Colorectal Cancer</i> , <b>2016</b> , 15, 360-368	3.8	24
46	The role of novel biologics in biliary cancers. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2016</b> , 62, 325-339	1.6	
45	Novel Therapeutics for Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , <b>2015</b> , 29, 777-87	3.1	11
44	FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 3512-21	3.1	112
43	Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , <b>2015</b> , 14, 269-76.e1	3.8	17
42	Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 93, 444-53	4	8
41	(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 1857-64	7.5	20
40	Identification of germline genetic mutations in patients with pancreatic cancer. <i>Cancer</i> , <b>2015</b> , 121, 4382-8	6.4	117
39	A phase I trial of binimetinib in combination with gemcitabine (G) and cisplatin (C) patients (pts) with untreated advanced biliary cancer (ABC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15125-e15125	2.2	5
38	Hepatocellular carcinoma (HCC) and bone metastases (Mets).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15129-e15129	2.2	1
37	Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15146-e15146	2.2	2

36	Phase II trial of veliparib (V) in patients (pts) with previously treated BRCA or PALB2-mutated (mut) pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 358-358	2.2	1
35	A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. <i>Pancreatology</i> , <b>2014</b> , 14, 398-402	3.8	13
34	A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. <i>Annals of Surgery</i> , <b>2014</b> , 260, 142-8	7.8	100
33	DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance. <i>Pancreas</i> , <b>2014</b> , 43, 1264-70	2.6	27
32	Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5281-9	12.9	42
31	Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4023-4023	2.2	16
30	Treatment, outcomes, and clinical trial participation in very elderly patients (pts) with metastatic pancreas cancer (mPC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4119-4119	2.2	3
29	Evaluation of PARP inhibition as a platinum sparing strategy in Brca2-deficient pancreatic tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15237-e15237	2.2	3
28	Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for therapeutic intent.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4136-4136	2.2	
27	Pharmacogenomic modeling of pancreatic cancer (PDAC) for prediction of chemotherapy response and resistance in second-line treatment setting.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4130-4130	2.2	
26	Feasibility and results of a randomized phase II study of fractionated 90Y-ivabuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4026-4026	2.2	1
25	Liver and Bile Duct Cancer <b>2014</b> , 1373-1396.e8		1
24	Molecular features of BRCA1/2 and PALB2 mutation associated pancreatic cancer (PAC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 206-206	2.2	
23	Molecular Chaperones and How Addiction Matters in Cancer Therapy <b>2013</b> , 181-203		0
22	Identification of germline genetic mutations in patients with pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 159-159	2.2	
21	Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 142-142	2.2	
20	Genomics and pharmacogenomics of pancreatic adenocarcinoma. <i>Pharmacogenomics Journal</i> , <b>2012</b> , 12, 1-9	3.5	10
19	A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management. <i>Journal of Gastrointestinal Cancer</i> , <b>2012</b> , 43, 314-8	1.6	1



18	Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. <i>Cancer Journal (Sudbury, Mass ), 2012, 18, 609-13</i>	2.2	11
17	Inhibition of poly (ADP-ribose) polymerase-1 (PARP-1) to increase radiosensitivity of human pancreatic cancer (PAC) cell lines proficient in homology-directed repair (HDR).. <i>Journal of Clinical Oncology, 2012, 30, 204-204</i>	2.2	4
16	A case of synchronous pancreatic ductal adenocarcinoma and ovarian mucinous cystic neoplasm: use of kras mutation molecular phenotyping to demonstrate independent primary origin. <i>Gastrointestinal Cancer Research: GCR, 2012, 5, 67-70</i>		4
15	A case of advanced gastric cancer. <i>Gastrointestinal Cancer Research: GCR, 2012, 5, 59-63</i>		1
14	A 72-year-old man with duodenal adenocarcinoma. <i>Gastrointestinal Cancer Research: GCR, 2012, 5, 93-6</i>		
13	Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma. <i>Gastrointestinal Cancer Research: GCR, 2012, 5, 130-4</i>		2
12	Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer. <i>Journal of Gastrointestinal Cancer, 2011, 42, 46-9</i>	1.6	
11	A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Cancer, 2011, 42, 160-4</i>	1.6	11
10	Gastrointestinal cancer educational case series: management of metastatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor. <i>Journal of Gastrointestinal Cancer, 2011, 42, 165-70</i>	1.6	0
9	A woman with remotely treated pancreas cancer and new abdominal pain: a discussion of evaluation and management. <i>Journal of Gastrointestinal Cancer, 2011, 42, 236-40</i>	1.6	0
8	New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. <i>BioDrugs, 2011, 25, 207-16</i>	7.9	7
7	An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. <i>Oncologist, 2011, 16, 1397-402</i>	5.7	190
6	Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy. <i>Oncologist, 2011, 16, 1714-20</i>	5.7	107
5	Clinical outcomes in pancreatic adenocarcinoma (PAC) associated with a known BRCA mutation.. <i>Journal of Clinical Oncology, 2011, 29, 268-268</i>	2.2	1
4	Hepatocellular carcinoma following renal transplantation. <i>Gastrointestinal Cancer Research: GCR, 2011, 4, 180-3</i>		
3	Clinical outcomes in patients age 40 or younger at diagnosis of synchronous metastatic colorectal cancer.. <i>Journal of Clinical Oncology, 2011, 29, 531-531</i>	2.2	
2	Pancreatic cancer: the role of molecular markers in diagnosis and management. <i>Clinical Advances in Hematology and Oncology, 2011, 9, 900-8</i>	0.6	5
1	Targeted therapies for pancreatic adenocarcinoma. <i>Minerva Chirurgica, 2009, 64, 501-19</i>	0.8	1

